# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
DarioHealth (NASDAQ:DRIO) reported quarterly sales of $5.758 million which missed the analyst consensus estimate of $6.758 mill...
Quasi-randomized study demonstrates the value of Dario's integrated approach to provide one solution for members to manage ...
Dario selected to provide integrated and proven solutions to improve employee cardiometabolic healthNEW YORK, April 18, 2024 /P...
Studies include a Randomized Controlled Trial demonstrating significant reduction in perceived stress for teens
DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, annou...
Stifel analyst David Grossman maintains DarioHealth (NASDAQ:DRIO) with a Buy and maintains $4 price target.
DarioHealth (NASDAQ:DRIO) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.54) b...
DarioHealth (NASDAQ:DRIO) reported quarterly sales of $3.62 million which beat the analyst consensus estimate of $3.57 million ...